The standard chemotherapy for patients with unresectable cholangiocarcinoma is gemcitabine plus cisplatin, and gemcitabine plus S-1 (GS) chemotherapy is also reported to have similar effectiveness in Japan. However, the response rates of these two chemotherapies were modest, and no patients with intrahepatic cholangiocarcinoma (ICC) have shown a pathological complete response (pCR) following these chemotherapies. We report here the first case of an initially unresectable locally advanced ICC that achieved pCR following GS chemotherapy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg. 2011;146:683–9.
Kato A, Shimizu H, Ohtsuka M, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20:318–24.
Sumiyoshi T, Shima Y, Okabayashi T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg. 2018;42:2910–8.
Leonard GD, O’Reilly EM. Biliary tract cancers: current concepts and controversies. Expert Opin Pharmacother. 2005;6:211–23.
Miyakawa S, Ishihara S, Horiguchi A, et al. Biliary tract cancer treatment: 5548 results from the biliary tract cancer statistics registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009;16:1–7.
Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463–75.
Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16:14–22.
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. ABC-02 trial Investigators. N Engl J Med. 2010;362:1273–81.
Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30:1950–8.
Lu J, Li B, Li FY, et al. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma involving the hepatic hilus versus hilar cholangiocarcinoma after curative-intent resection: should they be recognized as perihilar cholangiocarcinoma or differentiated? Eur J Surg Oncol. 2019;45:2173–9.
Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5:824–30.
Kanai M, Hatano E, Kobayashi S, et al. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer Chemother Pharmacol. 2015;75:293–300.
Abudalou M, Vega EA, Kondratiev S, et al. Complete pathological response to neoadjuvant chemoimmunotherapy in a patient with metastatic intrahepatic cholangiocarcinoma with high tumor mutational burden. Cureus. 2021;5(13): e20187.
Matsubara T, Nishida T, Tomimaru Y, et al. Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine/cisplatin/S-1 combination chemotherapy: a case report. Mol Clin Oncol. 2016;5:757–61.
Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22(Suppl 3):S1093–9.
Kobayashi H, Murakami Y, Uemura K, et al. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann Surg. 2012;256:288–96.
Sasaki H, Murakami Y, Uemura K, et al. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. Br J Cancer. 2014;111:1275–84.
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II keynote-158 study. J Clin Oncol. 2020;38:1–10.
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.
Lee V, Murphy A, Le DT, et al. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist. 2016;21:1200–11.
Akagi K, Oki E, Taniguchi H, et al. The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci. 2021;112:1105–13.
Eguchi S, Shinkawa H, Sato Y, et al. Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report. Clin J Gastroenterol. 2021;14:858–65.
Toshida K, Itoh S, Yoshizumi T. Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. Clin J Gastroenterol. 2021;14:1459–63.
Kai Y, Ikezawa K, Takada R, et al. Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer. JGH Open. 2021;5:712–6.
Abudalou M, Vega EA, Kondratiev S, et al. Complete pathological response to neoadjuvant chemoimmunotherapy in a patient with metastatic intrahepatic cholangiocarcinoma with high tumor mutational burden. Cureus. 2021;13: e20187.
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in this study involving human participants were in accordance with the institutional ethics committee and with the 1964 Helsinki Declaration and its later amendments.
Informed consent was obtained from the patient included in this study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sumiyoshi, T., Uemura, K., Shintakuya, R. et al. A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy. Clin J Gastroenterol 15, 1164–1168 (2022). https://doi.org/10.1007/s12328-022-01700-x